{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiczp7ytmm5jgwwlmmkkb4kgzxul4iuveubw72f3mobwvvveylzuva",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mhum5mjes6u2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihqqbfj4qnrnmpyei3sthscf6tfqa4dvig7ij7rwcmtm2p5jt7nhm"
    },
    "mimeType": "image/jpeg",
    "size": 65011
  },
  "path": "/pharmalot/2026/03/24/pharma-doctor-kickback-penalties-dwarfed-by-sales-revenue/?utm_campaign=rss",
  "publishedAt": "2026-03-24T17:36:10.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharmalot",
    "Pharmaceuticals",
    "Policy",
    "STAT+"
  ],
  "textContent": "Drugmakers that were penalized for kickbacks paid only 2.2% of their U.S. revenue generated by selling drugs that were the focus of the alleged violations during the past quarter century.",
  "title": "STAT+: Drug company penalties for paying kickbacks to doctors failed to dent  bottom lines, analysis finds",
  "updatedAt": "2026-03-24T18:27:57.000Z"
}